In-depth analysis for TKI-driven real-world management of 201 CML patients using TFR
In this Romanian center, imatinib was the predominant front-line TKI, reflecting both its earlier availability as the sole treatment option and the durable responses achieved by many long-term patients, but second-generation agents are increasingly used in over 40% of first-line starts. TFR uptake is limited despite a sizeable eligible population. Machine learning models demonstrate that both the depth and kinetics of molecular response are critical for predicting TFR potential. Prospective optimization of molecular monitoring and discontinuation protocols may broaden TFR success.
Authors
- Anca Bojan (ORCID: https://orcid.org/0000-0003-1523-3133)
- Adrian P. Trifa (ORCID: https://orcid.org/0000-0002-0229-8643)
- Diana Lighezan
- M Micu
- Adrian Bogdan Țigu (ORCID: https://orcid.org/0000-0001-9397-0791)
- Tunde Torok (ORCID: https://orcid.org/0000-0001-7667-9660)
- Laura Jimbu (ORCID: https://orcid.org/0000-0002-2323-3101)
- Anca Vasilache
- Andrada Pârvu (ORCID: https://orcid.org/0000-0002-5152-6040)
- Mihnea Zdrenghea (ORCID: https://orcid.org/0000-0002-9461-987X)
- Laura Urian
- Maria Santa (ORCID: https://orcid.org/0000-0003-4279-3574)
- Delia Dima
- Ciprian Tomuleasa (ORCID: https://orcid.org/0000-0002-5770-7811)
- Andrei Ivancuta
- Elena-Cristina Selicean
- Rus Ioana Codruța
- Simion Florin Cira
- Bancos Anamaria
Institutions
- Iuliu Hațieganu University of Medicine and Pharmacy (RO)
- Victor Babeș University of Medicine and Pharmacy Timișoara (RO)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.3389/fphar.2025.1673056
- Citations
- 1
- Primary Topic
- Chronic Myeloid Leukemia Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77
Funders
- Ministerul Cercetării, Inovării şi Digitalizării
- European Commission
- HORIZON EUROPE Framework Programme